Abstract 190P
Background
Although grade is strongly predictive of survival, no other prognostic or predictive biomarkers have been validated to help guide therapeutic decision making in Appendiceal adenocarcinomas (AA). Here we investigated the clinical utility of the serum tumor markers CEA, CA19-9, and CA-125 by association with survival and tumor molecular features.
Methods
The MD Anderson patient database was queried to identify a total of 1,322 patients diagnosed with of AA between 1997 to 2022 with at least one TM measured. Elevation of TM defined as above laboratory ULN (CEA > 3 ng/mL, CA 19-9 > 37 U/mL, and CA-125 > 37 U/mL, highly elevated defined as top 10th percentile (CEA > 100.4 ng/mL, CA 19-9 > 337.5 U/mL, and CA-125 > 41.8 U/mL).
Results
CEA, CA19-9 and CA125 were elevated in 56%, 34%, and 37% of patients, respectively, 63.8% had at least one elevated. The proportion of patients with elevation of each TM did not differ in high- vs low-grade tumors or by histologic subtype (mucinous, colonic, goblet, signet ring). CEA stratified patients by survival with median not-yet-reached for patients with normal CEA vs 182 mo for those with elevated CEA vs 96 mo for those with highly elevated CEA (log-rank p < 0.0001), 5-year OS was 95% vs 82% vs 61% for normal, elevated, and highly elevated, respectively. The prognostic effect of CEA was independent of grade, with 5-year OS (99%, 93%, 69%, log-rank p < 0.0001) for low-grade and (91%, 73%, 55%, log-rank p < 0.0001). Similar survival stratification was seen for CA19-9 (92%, 84%, 66%, log-rank p < 0.0001) and CA-125 (93%, 70%, 60%, log-rank p < 0.0001). CEA was more correlated with CA-19-9 (pearson r = 0.62) than CA-125 (r = 0.29). Elevation of multiple TM was associated with worse prognosis; HR relative to patients with no TM elevated was 4.9 (p = 6.0e-6), 8.9 (p = 6.5e-12), and 16.2 (p = 8.0e-16), for 1, 2, or all 3 TM in multivariate cox model of survival including gender, race, age, grade, and histologic subtype.
Conclusions
Elevation of CEA, CA19-9 and CA125 are independently associated with poor prognosis in patients with appendiceal cancer, all three should be measured. Future efforts to evaluate incorporation of TM into clinical staging are warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
University of Texas MD Anderson Cancer Center, Cancer Prevention Research Institute of Texas.
Disclosure
J. P. Y-C. Shen: Financial Interests, Personal, Other, general consultation and expert testimony: ShenJPMD Inc; Financial Interests, Personal, Other, advisory board: Engine Biosciences, NaDeNo Nanosciences; Financial Interests, Institutional, Coordinating PI, research project: Celsius Therapeutics; Financial Interests, Institutional, Other, research funding for pilot project: BostonGene. M.J. Overman: Financial Interests, Personal, Advisory Board: Roche, BMS, MedImmune, Merck, Amgen, Takeda, Janssen, Pfizer, Array, Gritstone, Nouscom, Atreca, Bayer; Financial Interests, Institutional, Coordinating PI: Roche, Lilly, Merck, BMS, Phanes, Nouscom. All other authors have declared no conflicts of interest.
Resources from the same session
227P - Biomarkers for novel NK checkpoint inhibitor anti LLT1 antibody, ZM008: Patient transcriptome analysis
Presenter: M. S. Madhusudhan
Session: Poster session 01
228P - Biomarker discovery via meta-analysis of immunotherapy clinical trials in cancer
Presenter: Benjamin Haibe-Kains
Session: Poster session 01
230P - Fibroblast growth factor receptor (FGFR) co-alteration (co-alt) landscape and its impact on erdafitinib (erda) response in the phase II open-label, single-arm RAGNAR trial
Presenter: Yohann Loriot
Session: Poster session 01
231P - Time to deterioration of quality of life as a surrogate of OS: A trial-level surrogacy analysis
Presenter: Adel Shahnam
Session: Poster session 01
232P - Identification of ‘secondary’ germline cancer predisposition variants from somatic tumour testing: Should we evolve towards universal screening?
Presenter: Alejandro Gallego Martinez
Session: Poster session 01